Simultaneous knockdown of APRIL via multiple shRNAs reduces the malignancy of SW480 cells

Oncology Reports

Volumn 28, Issue 5, 2012, Pages 1613-1618

  Li, Haiquan ^a   Shao, Keke ^b   Wang, Jingchun ^a   Wang, Guihua ^a   Xu, Jin ^a   Cao, Jinde ^a   Ju, Shaoqing ^a   Wang, Huimin ^a  

^a NANTONG UNIVERSITY   (China)

^b Yancheng City No1 People's Hospital   (China)

Author keywords

APRIL; Colon carcinoma; Multiple shRNAs; RNA interference; SW480

Indexed keywords

APRIL PROTEIN; MESSENGER RNA; SHORT HAIRPIN RNA;

A PROLIFERATION INDUCING LIGAND GENE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CELL ADHESION; CELL PROLIFERATION; COLON CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REAL TIME POLYMERASE CHAIN REACTION; RNA VECTOR; SEQUENCE ANALYSIS; TUMOR GENE;

APOPTOSIS; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM INVASIVENESS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 84866438176     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1980     Document Type: Article

References (35)

1. Hahne M, Kataoka T, Schröter M, Hofmann K, Irmler M, Bodmer JL, Schneider P, Bornand T, Holler N, French LE, et al: APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 188: 1185-1190, 1998. (Pubitemid 28443341)
2. Kimberley FC, van Bostelen L, Cameron K, Hardenberg G, Marquart JA, Hahne M and Medema JP: The proteoglycan (heparan sulfate proteoglycan) binding domain of APRIL serves as a platform for ligand multimerization and cross-linking. FASEB J 23: 1584-1595, 2009.
3. Deshayes F, Laprée G, Portier A, Richard Y, Pencalet P, Mahieu-Caputo D, Horellou P and Tsapis A: Abnormal production of the TNF-homologue APRIL increases the proliferation of human malignant glioblastoma cell lines via a specific receptor. Oncogene 23: 3005-3012, 2004. (Pubitemid 38648191)
4. Sun B, Wang H, Wang X, Huang H, Ding W, Jing R, Shi G and Zhu L: A proliferation-inducing ligand: a new biomarker for non-small cell lung cancer. Exp Lung Res 35: 486-500, 2009.
5. Mhawech-Fauceglia P, Kaya G, Sauter G, McKee T, Donze O, Schwaller J and Huard B: The source of APRIL up-regulation in human solid tumor lesions. J Leukoc Biol 80: 697-704, 2006. (Pubitemid 44835884)
6. Planelles L, Medema JP, Hahne M and Hardenberg G: The expanding role of APRIL in cancer and immunity. Curr Mol Med 8: 829-844, 2008.
7. Wang F, Chen L, Mao ZB, Shao JG, Tan C and Huang WD: Lentivirus-mediated short hairpin RNA targeting the APRIL gene suppresses the growth of pancreatic cancer cells in vitro and in vivo. Oncol Rep 20: 135-139, 2008.
8. Moreaux J, Veyrune JL, De Vos J and Klein B: APRIL is overexpressed in cancer: link with tumor progression. BMC Cancer 9: 83, 2009.
9. Dillon SR, Gross JA, Ansell SM and Novak AJ: An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 5: 235-246, 2006. (Pubitemid 43336036)
10. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE and Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811, 1998. (Pubitemid 28099681)
11. Cogoni C and Macino G: Post-transcriptional gene silencing across kingdoms. Curr Opin Genet Dev 10: 638-643, 2000.
12. Sioud M: Therapeutic siRNAs. Trends Pharmacol Sci 25: 22-28, 2004.
13. Wang S, Shi Z, Liu W, Jules J and Feng X: Development and validation of vectors containing multiple siRNA expression cassettes for maximizing the efficiency of gene silencing. BMC Biotechnol 6: 50, 2006.
14. Ding W, Wang J, Sun B, Ju S, Yuan H, Wang X, Wang Y and Wang H: APRIL knockdown suppresses migration and invasion of human colon carcinoma cells. Clin Biochem 42: 1694-1698, 2009.
15. Hendriks J, Planelles L, de Jong-Odding J, Hardenberg G, Pals ST, Hahne M, Spaargaren M and Medema JP: Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ 12: 637-648, 2005. (Pubitemid 40767166)
16. Rennert P, Schneider P, Cachero TG, Thompson J, Trabach L, Hertig S, Holler N, Qian F, Mullen C, Strauch K, Browning JL, Ambrose C and Tschopp J: A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J Exp Med 192: 1677-1684, 2000.
17. Marsters SA, Yan M, Pitti RM, Haas PE, Dixit VM and Ashkenazi A: Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol 10: 785-788, 2000. (Pubitemid 30466942)
18. Wu Y, Bressette D, Carrell JA, Kaufman T, Feng P, Taylor K, Gan Y, Cho YH, Garcia AD, Gollatz E, et al: Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J Biol Chem 275: 35478-35485, 2000.
19. Esko JD and Lindahl U: Molecular diversity of heparan sulfate. J Clin Invest 108: 169-173, 2001. (Pubitemid 32656238)
20. Gallagher JT: Heparan sulfate: growth control with a restricted sequence menu. J Clin Invest 108: 357-361, 2001.
21. Perrimon N and Bernfield M: Specificities of heparan sulphate proteoglycans in developmental processes. Nature 404: 725-728, 2000. (Pubitemid 30212391)
22. Hayashida K, Johnston DR, Goldberger O and Park PW: Syndecan-1 expression in epithelial cells is induced by transforming growth factor beta through a PKA-dependent pathway. J Biol Chem 281: 24365-24374, 2006. (Pubitemid 44274208)
23. Ding W, Ju S, Jiang S, Zhu L, Wang Y and Wang H: Reduced APRIL expression induces cellular senescence via a HSPG-dependent pathway. Pathol Oncol Res 15: 693-701, 2009.
24. Hannon GJ: RNA interference. Nature 418: 244-251, 2002.
25. Dykxhoorn DM: RNA interference as an anticancer therapy: a patent perspective. Expert Opin Ther Pat 19: 475-491, 2009.
26. Wang SL, Yao HH and Qin ZH: Strategies for short hairpin RNA delivery in cancer gene therapy. Expert Opin Biol Ther 9: 1357-1368, 2009.
27. Gou D, Weng T, Wang Y, Wang Z, Zhang H, Gao L, Chen Z, Wang P and Liu L: A novel approach for the construction of multiple shRNA expression vectors. J Gene Med 9: 751-763, 2007. (Pubitemid 47386860)
28. Yan Y, Zhang J, Guo JL, Huang W and Yang YZ: Multiple shRNA-mediated knockdown of TACE reduces the malignancy of HeLa cells. Cell Biol Int 33: 158-164, 2009.
29. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
30. Center MM, Jemal A, Smith RA and Ward E: Worldwide variations in colorectal cancer. CA Cancer J Clin 59: 366-378, 2009.
31. Ortega J, Vigil CE and Chodkiewicz C: Current progress in targeted therapy for colorectal cancer. Cancer Control 17: 7-15, 2010.
32. Markowitz SD and Bertagnolli MM: Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 361: 2449-2460, 2009.
33. Jazag A, Kanai F, Ijichi H, Tateishi K, Ikenoue T, Tanaka Y, Ohta M, Imamura J, Guleng B, Asaoka Y, et al: Single small-interfering RNA expression vector for silencing multiple transforming growth factor-beta pathway components. Nucleic Acids Res 33: e131, 2005.
34. ter Brake O, Konstantinova P, Ceylan M and Berkhout B: Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther 14: 883-892, 2006. (Pubitemid 44743127)
35. Song J, Giang A, Lu Y, Pang S and Chiu R: Multiple shRNA expressing vector enhances efficiency of gene silencing. BMB Rep 41: 358-362, 2008. (Pubitemid 351793227)